Dahllöf G, Preber H, Eliasson S, Rydén H, Karsten J, Modéer T
Department of Pedodontics, School of Dentistry, Karolinska Institutet, Stockholm, Sweden.
Epilepsia. 1993 Sep-Oct;34(5):960-4. doi: 10.1111/j.1528-1157.1993.tb02118.x.
The periodontal condition of 40 adult epileptic subjects (mean age 51 years) receiving long-term therapy (mean 18 years) with phenytoin (PHT) or carbamazepine (CBZ) was studied. The subjects completed a questionnaire and underwent clinical and radiologic examination. Patients receiving PHT exhibited the same level of alveolar bone loss as those receiving CBZ. Patients receiving PHT exhibited more units with gingival overgrowth, reflected by the significantly higher number of gingival units with increased probing depth (p < 0.05). The results indicate that long-term PHT does not result in increased risk for alveolar bone loss as compared with CBZ.
对40名接受苯妥英（PHT）或卡马西平（CBZ）长期治疗（平均18年）的成年癫痫患者（平均年龄51岁）的牙周状况进行了研究。这些受试者完成了一份问卷，并接受了临床和放射学检查。接受PHT治疗的患者牙槽骨丧失水平与接受CBZ治疗的患者相同。接受PHT治疗的患者牙龈增生单位更多，这表现为探诊深度增加的牙龈单位数量显著更高（p<0.05）。结果表明，与CBZ相比，长期使用PHT不会增加牙槽骨丧失的风险。
